Pharmacy Dead Stock: How Much Is It Really Costing You?

Quick Answer

Pharmacy dead stock is inventory that has not moved in roughly four months and has no realistic path to selling before its batch expires. The visible cost is the write-off. Underneath it sit three costs that never reach that line — the capital it locked up, the cost of holding it, and a GST reversal — and it is those that make the total hurt. Industry data puts the value of a pharmacy's average inventory that expires each year at about 10%, of which roughly 80% is returnable for credit — so the stock that actually dies is the unreturnable remainder. On top of that sits a carrying cost of 20-30% of inventory value a year, and, in India, a Section 17(5)(h) GST reversal that claws back the Input Tax Credit you already claimed on goods you are about to destroy.

Put those together on a store carrying ₹15,00,000 of stock and the arithmetic is uncomfortable. A 2% unreturnable write-off is ₹30,000 gone outright; the ITC reversal on it adds roughly ₹1,500 at the 5% rate almost all finished formulations have attracted since the September 2025 rate rationalisation; and the capital sat in slow stock all year instead of funding the fast movers. None of it appears as a line item called "dead stock" — which is exactly why it survives for years.

Expiry, return and return-fee percentages are US community-pharmacy industry benchmarks, and the 20-30% carrying cost is from an NCPA study, all as reported in the analysis linked above — the best-measured numbers available for retail pharmacy anywhere. Indian margins are thinner, so the same percentages hurt more, not less.

What Counts as Dead Stock — and What Doesn't

The most expensive mistake in inventory management is not dead stock itself. It is treating slow-moving stock as if it were dead, or dead stock as if it were merely slow. They need opposite responses, and both errors cost money.

The separating test is a sales-velocity check. Take units dispensed over the trailing 90 days, divide by 90 to get a daily rate, and multiply by the days remaining until the batch expires. If that number is smaller than the quantity on the shelf, the difference is dead by definition — it physically cannot sell in time. Run it batch-wise, not product-wise: a fast-moving molecule can still be sitting on one stranded batch with four weeks left on it.

The Three Costs That Never Reach the Write-Off Line

Most pharmacy owners know what the expiry bin cost them. Almost none know what the shelf cost them. There are three layers underneath the visible number.

• Opportunity cost: Capital locked in stock that will not sell is capital not funding the chronic refills that actually turn. The store then either under-stocks its bestsellers — and the patient walks to the shop next door for the rest of the basket too — or leans harder on supplier credit, adding finance cost on top of the original loss.
• Carrying cost: Storage, cold-chain power, insurance, security, shrinkage and the cost of the capital itself run to 20-30% of inventory value per year. Dead stock is not merely worth nothing; it bills you every month it stays.
• Recovery cost: Even the value you do get back is not returned whole. Reverse-logistics processing runs around 8% of the returned value, and Indian manufacturers typically settle expiry claims net of a breakage allowance and on a delayed credit-note cycle.

There is a fourth layer that only shows up at filing time, and it is the one this article spends the most space on, because it is the one most stores discover after the fact rather than before: the GST Input Tax Credit you claimed when you bought the stock does not survive its destruction.

Why Manual Tracking Loses This Fight

This is not primarily a large-chain problem. Independent stores are more exposed, not less: they add SKUs faster than any manual system can absorb, rarely have anyone whose job is inventory, and run on tighter cash with heavier reliance on distributor credit. A mid-sized Indian pharmacy carries 800 to 3,000 SKUs, each split across batches with their own expiry dates — several thousand date-bearing objects, revalued daily. Paper registers and spreadsheets are not a weak solution at that scale. They are an arithmetically impossible one.

Failure one: FIFO habits on a FEFO problem

Staff under counter pressure reach for the nearest box, not the one expiring first. The distinction matters because pharmaceutical supply chains are not linear — a batch delivered this week can carry an earlier expiry than one that has been on the shelf since March. First-In-First-Out gets the older purchase out; only First-Expired-First-Out gets the nearer expiry out, and only one of those protects you. Without a system that surfaces the shortest-dated batch at the moment of billing, FEFO stays a policy on a wall rather than a behaviour at a counter.

Failure two: the return window closes quietly

Indian expiry returns move up the chain you bought through — retailer to stockist, stockist to manufacturer — and the practical window is narrow. Most companies accept a claim in or around the month of expiry itself, issue a credit note net of a breakage or expiry allowance in the region of 0.5-2%, and settle it over a subsequent cycle rather than immediately. Miss the batch, and the same carton that was worth a credit note last month is worth nothing this month except a disposal cost. Nothing in a paper register announces that transition.

The Four KPIs That Tell You If You Have a Problem

Gut feel is not a metric, and "stock looks heavy" is not a diagnosis. Four numbers, tracked monthly, will tell you more than a year of walking the aisles.

Those four are not independent — they are four views of the same cash. A store turning stock 12 times a year is holding about a month of supply, which mechanically produces a GMROI near 3 at the 20-22% blended margin a balanced Indian product mix typically earns. When the four stop agreeing with each other, the disagreement is usually dead stock inflating the denominator.

ABC-VED: Where to Spend Your Attention First

You cannot monitor 3,000 SKUs with equal intensity, and you should not try. Indian hospital pharmacies have used the ABC-VED matrix for decades to decide where the attention goes: ABC ranks items by annual spend, VED ranks them by clinical criticality, and the cross-tabulation tells you which cells deserve continuous review.

The concentration is stark. In a published analysis of the drug store at PGIMER Chandigarh, 13.78% of items accounted for 69.97% of annual drug expenditure; on the combined matrix, the 22.09% of items falling into Category I consumed 74.21% of the budget, while the 23.28% in Category III accounted for 3.56%. Different store, similar shape — roughly a fifth of your catalogue is where nearly all of your money is.

The GST Trap: Dead Stock Costs More Than the Stock

This is the part that surprises people. Section 17(5)(h) of the CGST Act, 2017 blocks Input Tax Credit on goods "lost, stolen, destroyed, written off or disposed of by way of gift or free samples." Dead stock ends up written off and destroyed without ever being taxably sold — so the ITC you legitimately claimed when you bought it becomes ineligible after the fact, and has to be reversed.

• Reverse in the month you write it off: The reversal belongs to the tax period in which the goods are written off or destroyed, not to a year-end true-up. Carrying it forward is what turns a clean adjustment into an interest-bearing one.
• Report it in GSTR-3B Table 4(B)(1): That row is labelled for reversals under rules 38, 42 and 43 and for ineligible credit under Section 17(5) — permanent reversals that are never reclaimed. It is the correct cell for destroyed stock, and putting it anywhere else is what an audit picks up.
• Keep the destruction evidence with the return: The batch list, the quantity, the disposal manifest and the date. The reversal is a self-assessed entry, so the file that justifies it is the only thing standing between you and a retrospective demand.

Both routes are set out in the circular clarifying the procedure for return of time-expired drugs or medicines. The routes differ in where the reversal lands: on a fresh invoice the retailer keeps its purchase ITC and the party that destroys the goods reverses the credit on the return supply; on a credit note the retailer must have reversed or never claimed that purchase ITC before the supplier can adjust its own tax. And a credit note only adjusts the supplier's tax liability if it is issued within the time limit in Section 34(2); issued later, it is still a valid commercial document — it simply no longer moves the tax.

Disposal: You Cannot Simply Bin It

Expired medicine is regulated waste. Under the Bio-Medical Waste Management Rules, 2016, discarded and expired medicines sit in the yellow category, and the CPCB's healthcare waste guidelines are explicit about where they may go: back to the manufacturer, or to a Common Bio-Medical Waste Treatment Facility for incineration — and for cytotoxic drugs specifically, incineration at over 1200°C. Municipal waste is not an option, and neither is the drain.

For a retail chemist the practical route is almost always the first one — expired stock goes back through the stockist who supplied it, which settles the disposal question and the credit question in the same movement. Where that is not possible, the CPCB guidance is that the medicines go to a CBWTF rather than being handled in-house. Either way, what an inspector wants is the paper trail: what was identified, when it was isolated, where it went, and who signed for it.

Penalties for contravention now flow through Section 15 of the Environment (Protection) Act, 1986 as amended by the Jan Vishwas (Amendment of Provisions) Act, 2023, which replaced imprisonment with monetary penalties plus a further amount for each day a contravention continues. Published summaries of the revised figures disagree with one another, so treat the amount as a question for your State Pollution Control Board rather than for a blog — this one included.

How to Actually Bring Dead Stock Down

1. 1

   Separate slow from dead before you write anything off

   Run the 90-day velocity check batch-wise. Stock that merely needs a discount or a prescriber reminder is not a write-off candidate, and treating it as one destroys real revenue.

2. 2

   Track the four KPIs monthly, not annually

   Turnover, days supply, GMROI and dead stock share. An annual stock count tells you what happened; a monthly reading tells you in time to act.

3. 3

   Apply ABC-VED so the attention lands where the money is

   Roughly a fifth of your catalogue carries three-quarters of your spend. Review that fifth continuously and let the cheap, non-critical tail look after itself.

4. 4

   Enforce FEFO at the billing screen

   A policy that depends on a busy person choosing the right box will fail. Batch-level tracking that surfaces the shortest-dated batch at the point of sale removes the choice.

5. 5

   Automate 90/60/30-day near-expiry alerts

   The point is to reach the return window while it is still open, and to leave enough runway to discount or transfer stock that will not be taken back.

6. 6

   Reverse the ITC in the same month you destroy the stock

   Post it to GSTR-3B Table 4(B)(1) with the batch evidence attached. A reversal found in an audit costs far more than the same reversal filed on time.

7. 7

   Dispose only through an authorised route, with the paperwork

   Back to the stockist, or to a CBWTF. Keep the manifest — the audit trail is the part that is hardest to reconstruct later.

What Software Actually Changes

A spreadsheet cannot forecast demand, cannot enforce FEFO at the counter, and cannot notice that a return window is about to shut. Those three gaps are most of the dead stock problem, and they are all mechanical rather than analytical — which is why software closes them reliably and willpower does not.

The forecasting half is the newest and the most oversold. Reported results from AI-driven pharmaceutical inventory deployments include a 25-30% reduction in forecast error and the elimination of around 80% of critical stockouts, and published research on hospital drug stores reports stockout reductions in the mid-20% range alongside similar cuts in overstocking. Read those as directional: the strongest figures come from vendor case studies rather than controlled trials, and a retail chemist's demand curve is not a tertiary hospital's.

The unglamorous half is the half that pays. Batch-wise expiry visibility, a 90/60/30-day alert that reaches someone who can act on it, and a billing screen that offers the shortest-dated batch first are not predictions — they are bookkeeping done at the speed the shop actually runs. This is the gap BitMed's pharmacy inventory management is built to close for Indian retail pharmacies: expiry tracking at batch level, automated near-expiry alerts, and FEFO applied where the sale happens, without needing an inventory analyst on the payroll.

Frequently Asked Questions